Ocular Therapeutix Stock Filter Stocks by Fundamentals
| OCUL Stock | USD 9.89 0.17 1.69% |
Ocular Therapeutix fundamentals help investors to digest information that contributes to Ocular Therapeutix's financial success or failures. It also enables traders to predict the movement of Ocular Stock. The fundamental analysis module provides a way to measure Ocular Therapeutix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocular Therapeutix stock.
Ocular | Shares Owned by Institutions |
Ocular Therapeutix Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ocular Therapeutix from analyzing Ocular Therapeutix's financial statements. These drivers represent accounts that assess Ocular Therapeutix's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ocular Therapeutix's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 178.8M | 1.3B | 532.5M | 216.0M | 356.0M | 238.3M | |
| Enterprise Value | 183.7M | 1.1B | 427.3M | 178.0M | 243.6M | 200.8M |
Ocular Therapeutix ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ocular Therapeutix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ocular Therapeutix's managers, analysts, and investors.Environmental | Governance | Social |
Ocular Therapeutix Institutional Holders
Institutional Holdings refers to the ownership stake in Ocular Therapeutix that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ocular Therapeutix's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ocular Therapeutix's value.| Shares | State Street Corp | 2024-09-30 | 3.5 M | Perceptive Advisors Llc | 2024-09-30 | 3.3 M | Geode Capital Management, Llc | 2024-09-30 | 3.3 M | Assenagon Asset Management Sa | 2024-09-30 | 2.8 M | Deltec Asset Management Llc | 2024-09-30 | 2.6 M | Octagon Capital Advisors Lp | 2024-09-30 | 2.4 M | Braidwell Lp | 2024-09-30 | 2.2 M | Point72 Asset Management, L.p. | 2024-09-30 | 2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.6 M | Summer Road Llc | 2024-09-30 | 14.4 M | Vr Adviser, Llc | 2024-09-30 | 12.8 M |
Ocular Fundamentals
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.26) % | ||||
| Operating Margin | (2.65) % | ||||
| Current Valuation | 1.2 B | ||||
| Shares Outstanding | 157.22 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 91.07 % | ||||
| Number Of Shares Shorted | 10.78 M | ||||
| Price To Earning | (2.69) X | ||||
| Price To Book | 4.42 X | ||||
| Price To Sales | 25.89 X | ||||
| Revenue | 58.44 M | ||||
| Gross Profit | (6.51 M) | ||||
| EBITDA | (66.42 M) | ||||
| Net Income | (80.74 M) | ||||
| Cash And Equivalents | 134.54 M | ||||
| Cash Per Share | 1.75 X | ||||
| Total Debt | 83.39 M | ||||
| Debt To Equity | 0.90 % | ||||
| Current Ratio | 6.14 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (70.23 M) | ||||
| Short Ratio | 9.68 X | ||||
| Earnings Per Share | (1.29) X | ||||
| Target Price | 18.22 | ||||
| Number Of Employees | 267 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 1.58 B | ||||
| Total Asset | 252.06 M | ||||
| Retained Earnings | (697.58 M) | ||||
| Working Capital | 197.34 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 5.38 M | ||||
| Net Asset | 252.06 M |
About Ocular Therapeutix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ocular Therapeutix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocular Therapeutix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocular Therapeutix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Ocular Therapeutix Piotroski F Score and Ocular Therapeutix Altman Z Score analysis. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.